Won again to win the "Nobel Prize in the Medical Industry", Novartis shows a strong innovative strength

The International Galen Award, known as the "Nobel Prize in the Medicine Circle", has recently been announced. Novartis's Norvade III (Shakakuta Satan) once again won this award, which achieved great achievements.

Since the establishment of the Galen Award in 1970, Novartis can be described as the award -winning frequent visitor to the Galen Award, Nuo Cindee®, Keshan Tiri ® Various products such as Le® (Ogauzumab), Greei® (Imaidinib tablets) and Reevern ® (Aqubapo ethanol) have won the United States, the United Kingdom, and Canada Gai Lun Awards cover many major fields such as immunity, ophthalmology, leather, breathing, and blood diseases.

The Galen Award is recognized as the highest honor in the biomedical industry. Novartis can win many Galen prizes on multiple products.

Novartis can achieve these achievements. In addition to the advanced strategic layout on the product pipeline, it also benefits from applying digital technology to development in recent years.

Prospective layout of R & D Pipeline

In 1996, Sam Dezi and Steama-Jiaji announced the merger and became Nuohua today. But in the previous body, Novartis has more than 250 years of innovation history. Today's Novartis is one of the world's largest pharmaceutical companies. The product line and the rich area of ​​research pipelines and wide coverage areas are widely recognized in the industry.

In December last year, Novartis shared the latest R & D pipeline on the R & D date. At that time, the data showed that Novartis had 70 new molecular entities (NMES) projects, 65 projects were in the later stage of development, and 100 projects were in early development stage. About 85%of the product line therapy belongs to the first or specific indications of the same type. In the past six years, Novartis has obtained 23 FDA breakthrough therapy.

The progress of these pipelines comes from Novartis' continuous R & D investment and strong strategic layout. In 2021, Novartis's R & D investment was as high as US $ 9.54 billion, accounting for 18.48%of revenue.

Novartis has more than 20,000 R & D personnel worldwide, covering more than 50 diseases, and has strong strength in important diseases such as cardiovascular and kidney, tumors, hematology, immunity, and neurology. In the field of ophthalmology and breathing allergies, Novartis has innovative nature Test projects and listed products.

At present, Novartis is promoting more than 160 clinical trial projects at various stages, including more than 50 ongoing III clinical projects. At present, there are 14 heavy products on the market. Novartis expects that among the products approved by 2026, 20 will be expected to become heavy drugs, and annual sales may exceed $ 1 billion.

Digital technology in -depth application

Novartis has established five major technical platforms such as chemical and biological therapy, biological therapy, radiation ligand therapy, cytotherapy and gene therapy, laying a solid foundation for R & D and innovation in the next few years.

These five leading technical platforms provide Novartis with unique opportunities that can be used to develop related products, try new disease field development, and can also seek deeper capacity expansion by binding different technical platforms.

Novartis is also one of the first companies in the world to apply digital technology and data science to new drug research and development. With its own clinical trials, Novartis has collected data from about 2 million patients. The in -depth excavation of this massive data can provide guidance for the direction of Nuohua's clinical research and future research and development, and more targeted screening of effective molecules and drugs for diseases.

Novartis also set up a digital platform "Sense" for clinical trial management. As a unique "control tower", it can monitor hundreds of clinical trials that Novarton is conducting in real time, thereby optimizing the monitoring and management of clinical data, and reminding it Risk index of clinical trials.

Novartis also actively applies artificial intelligence and machine learning to drug development. In January 2019, Novartis announced the establishment of cooperation with the University of Oxford University of Big Data to predict the patient's response to the drug. In October of the same year, Novartis and Microsoft cooperated across the industry to establish a Nuohua AI Innovation Laboratory. It plans to apply AI technology to the entire drug research and development process, including research, clinical trials, production, operation and other links.

The application of these new technologies is expected to bring faster and more effective drug research and development pipelines.

Activate China's research and development power

In 2021, Novartis Group's global net sales reached 51.6 billion US dollars, of which 81%of the income from innovative drugs reached 81%.

In April of this year, Novartis announced the merger of the former Novarty Pharmaceutical and Novartis tumor to set up Novartis' innovative drugs to further focus on innovative drugs and a new generation of advanced therapies.

In recent years, China has continuously deepened the reform of medical and drug supervision, and continued to provide benefits for the development of new drugs. Novartis has further focused on drug development in China to accelerate the listing of new drugs and benefit patients.

Nuohua's R & D layout in China has provided help for the rapid development of innovative drug business. In 2006, the Novartis (China) Biomedical Research Center was established in Shanghai. In 2016, Novartis Shanghai Park was officially put into operation, and then became a R & D center for Novartis in China. At present, Nuohua's R & D team in China has more than 600 employees, distributed in major operating bases such as Shanghai, Beijing, and Changshu. At present, nearly 100 clinical projects are carried out in China.

The Nuohua China R & D team is actively implementing the "China Pharmaceutical Development Strategy" with Nuohua Global and China's cross -departments, supporting China to comprehensively participate in the clinical project of Nuohua's global drug development, help achieve synchronous development, simultaneous registration of China and global, and develop data and digital technology.Applications in clinical research to accelerate the introduction and development of Novartis.From 2015 to 2021, Novartis had more than 35 new drugs and new indications in China.Novartis predicts that in the next 5 years, it will submit a registration application for 50 new drugs and new indications in China, and in 2024, more than 90%of Chinese new drug registration will be synchronized with global synchronization.

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

### Domestic Innovation Pharmaceutical#

- END -